NASDAQ:ABP Abpro Q2 2025 Earnings Results & Report $0.52 0.00 (0.00%) As of 10/14/2026 Abpro reported Q2 2025 earnings on August 13, 2025. The company reported EPS of -$1.20. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 13, 2025TimeAfter Market Closes Abpro EPS ResultsActual EPS-$1.20Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAbpro Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile Abpro Q2 2025 Earnings FAQ Did Abpro beat earnings estimates for Q2 2025? Abpro (NASDAQ:ABP) reported earnings of -$1.20 per share for Q2 2025. The report was announced on Wednesday, August 13, 2025. Abpro Earnings HeadlinesAbpro Holdings Faces Nasdaq Delisting, Moves to OTCJune 23, 2026 | theglobeandmail.comAbpro Holdings Directors Resign, Board Seeks ReplacementsJune 22, 2026 | theglobeandmail.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 15 at 1:00 AM | Profits Run (Ad)ABPO Abpro Holdings, Inc.May 6, 2026 | seekingalpha.comAbpro Bio Co. Ltd.April 16, 2026 | barrons.comAbpro Holdings Equity Warrant Exp 12th Nov 2029April 14, 2026 | cnbc.comSee More Abpro Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Abpro? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Abpro and other key companies, straight to your email. Email Address About AbproAbpro (NASDAQ:ABP) is a clinical-stage biotechnology company focused on developing antibody-based therapeutics for cancer and other serious diseases. The company uses proprietary antibody discovery and engineering technologies to develop treatments designed to target disease-related proteins and stimulate targeted immune responses. Abpro’s research programs include bispecific antibodies, which are engineered to bind to two different targets, including approaches designed to direct immune cells toward cancer cells. Its pipeline has included candidates aimed at solid tumors and other oncology applications, although the development status and composition of individual programs may change as clinical and regulatory work progresses. The company has historically operated as an antibody therapeutics developer serving the global biopharmaceutical market. Abpro became publicly traded on the Nasdaq under the symbol ABP following its business combination and listing in 2024. Publicly available information about its current leadership and broader commercial operations is limited.View Abpro ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
